Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin-EIR in Moderate Active Crohn's Disease
NCT00528073Phase 2Completed
- Sponsor
- Alfasigma
- Start
- Sep 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in Crohn's disease (4 arms), sponsored by Alfasigma. Primary endpoint: Clinical remission (Crohn's Disease Activity Index < 150 points) at 12 weeks. Started Sep 2007; status: completed.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00528073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528073.